Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  SHENZHEN STOCK EXCHANGE  >  Hualan Biological Engineering Inc    002007   CNE000001JN8

HUALAN BIOLOGICAL ENGINEERING INC

(002007)
  Report  
No quotes available
-- CNY   --.--%
 SummaryRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (CNY)
Sales 2019 4 097 M
EBIT 2019 1 711 M
Net income 2019 1 457 M
Finance 2019 1 062 M
Yield 2019 1,11%
Sales 2020 4 770 M
EBIT 2020 1 997 M
Net income 2020 1 703 M
Finance 2020 1 179 M
Yield 2020 1,30%
P/E ratio 2019 33,2x
P/E ratio 2020 28,0x
EV / Sales2019 11,1x
EV / Sales2020 9,50x
Capitalization 46 483 M
More Financials
Company
Hualan Biological Engineering specializes in the research, development, manufacturing and marketing of biological and sanguine products and vaccines. The group's products include immunoglobulin for intravenous injections, lyophilized surgical fibrin, lyophilized thrombin for external use, vaccines... 
More about the company
Surperformance© ratings of Hualan Biological Engineer
Trading Rating : Investor Rating :
More Ratings
Latest news on HUALAN BIOLOGICAL ENGINEER

- No features available -

More news
Sector news : Bio Therapeutic Drugs
08/15European Medicines Agency Reviews Arthritis Treatment by Gilead, Galapagos
DJ
08/12REGENERON PHARMACEUTICALS : Two Experimental Ebola Drugs Reduce Mortality Rate
DJ
08/08Sarepta says adverse event report for DMD gene therapy erroneously submitted
RE
08/08AGENUS : FDA Accepts AGEN2373 IND, Triggering $7.5 Million Milestone
DJ
08/07NOVARTIS : Medicare Moves to Cover Costly Cell Therapies
DJ
More sector news : Bio Therapeutic Drugs
Chart HUALAN BIOLOGICAL ENGINEERING INC
Duration : Period :
Hualan Biological Engineering Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 30,57  CNY
Last Close Price 33,13  CNY
Spread / Highest target 6,65%
Spread / Average Target -7,72%
Spread / Lowest Target -39,8%
EPS Revisions
Managers
NameTitle
Kang An Chairman & General Manager
Peng Fei Zhang Chairman-Supervisory Board
Jun Min Xie Chief Financial Officer & Secretary
Bei Fan Director & Executive Deputy General Manager
Qi Ping Wang Director & Deputy General Manager
Sector and Competitors
1st jan.Capitalization (M$)
HUALAN BIOLOGICAL ENGINEERING INC6 503
GILEAD SCIENCES0.94%79 622
VERTEX PHARMACEUTICALS11.60%46 554
REGENERON PHARMACEUTICALS-20.52%32 073
GENMAB26.56%13 013
SAREPTA THERAPEUTICS INC14.50%9 067